Validation of PROMIS Banks With COPD Exacerbations
12. december 2012 opdateret af: University of North Carolina, Chapel Hill
The Patient-Reported Outcomes Measurement Information System (PROMIS) is an NIH Roadmap initiative to develop a computerized system measuring patient-reported outcomes in respondents with a wide range of chronic diseases and demographic characteristics.
In the first four years of its existence, the PROMIS network developed item banks for measuring patient-reported outcomes in the areas of pain, fatigue, emotional distress, physical function, and social functioning.
During the item banking process, the PROMIS network conducted focus groups, individual cognitive interviews, and lexile (reading level) analyses to refine the meaning, clarity, and literacy demands of all items.
The item banks were administered to over 20,000 respondents and calibrated using models based on item response theory (IRT).
Using these IRT calibrations, computerized adaptive test (CAT) algorithms were developed and implemented.
The network has designed a series of studies using clinical populations to evaluate the item attributes, examine their utility as CATs, and validate the item banks.
More information on the PROMIS network can be found at www.nihpromis.org.
Studieoversigt
Status
Afsluttet
Betingelser
Detaljeret beskrivelse
This is a prospective longitudinal study of adult patients with chronic obstructive pulmonary disease (COPD) who will be enrolled when their COPD is considered clinically stable or during an acute exacerbation. This design will allow both within-person and between-person comparisons by exacerbation experience. Comprehensive clinical and patient-reported assessments will be performed at baseline and at 3 months (end of study). Subsets of items will be administered by interactive voice response (IVR) over the course of the study to measure changes in key symptoms over the course of recovery from an exacerbation. A subset of patients will be interviewed at the end of the study to assess content validity of PROMIS items in this patient population.
With such a study design, we will be able to evaluate the validity of the PROMIS items in this patient population under acute and stable conditions and evaluate responsiveness of several PROMIS item banks under conditions of known change in an underlying chronic disease. We will also evaluate stability of sub-domains that are not hypothesized to change with COPD exacerbations.
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
188
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Illinois
-
Evanston, Illinois, Forenede Stater, 60201
- NorthShore University HealthSystem (Formerly Evanston Northwestern Healthcare)
-
-
North Carolina
-
Chapel Hill, North Carolina, Forenede Stater, 27599
- University of North Carolina at Chapel Hill
-
Durham, North Carolina, Forenede Stater, 27701
- Duke University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15261
- University of Pittsburgh
-
Pittsburgh, Pennsylvania, Forenede Stater, 15240
- Pittsburgh VA Hospital
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
40 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
People presenting to primary care or specialty clinics with COPD either with exacerbation or without exacerbation.
People admitted to the hospital with a COPD exacerbation.
Beskrivelse
Inclusion Criteria:
- An established clinical history of COPD in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) definition: COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients. Its pulmonary component is characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with an abnormal inflammatory response of the lung to noxious particles or gases.
- A history of smoking (at least 10 pack/year history)
- Access to and able to communicate on a touch tone telephone
- Read and speak English
- Able to see and interact with a computer screen, mouse, and keyboard
- A signed and dated written informed consent prior to study participation
- For those enrolled into the exacerbation group: Treatment for an exacerbation may have been started no more than 3 days prior to the day of enrollment for patients recruited in the outpatient setting and no more than 6 days prior to the day of enrollment for patients recruited in the in-patients setting.
- For those enrolled in the stable state group, the patient will be considered stable if he or she has been exacerbation-free for a minimum of 2 months prior to enrollment.
Exclusion Criteria:
- Any concurrent medical or psychiatric condition that may preclude participation in this study or completion of self-administered questionnaires (e.g., moderate to severe dementia and/or severe, uncontrolled schizophrenia, or other condition that would render the participant unable to complete a questionnaire)
- History of asthma without co-existent COPD as the primary diagnosis
- Experiencing a current heart failure exacerbation. (A diagnosis of heart failure is not in itself an exclusion criterion.)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Stable
Patients who are stable have not had a COPD exacerbation in the past 2 months.
|
|
Exacerbation
Patients with an exacerbation have been diagnosed and started on treatment for an exacerbation within the past 3 days.
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Darren A. Dewalt, MD, MPH, University of North Carolina, Chapel Hill
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. juli 2008
Primær færdiggørelse (Faktiske)
1. juni 2009
Studieafslutning (Faktiske)
1. juni 2009
Datoer for studieregistrering
Først indsendt
30. oktober 2008
Først indsendt, der opfyldte QC-kriterier
30. oktober 2008
Først opslået (Skøn)
2. november 2008
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
13. december 2012
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
12. december 2012
Sidst verificeret
1. december 2012
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 07-02
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .